{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:36:05Z","timestamp":1766428565136,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T00:00:00Z","timestamp":1392163200000},"content-version":"vor","delay-in-days":195,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["N01MH90001","R01MH064173"],"award-info":[{"award-number":["N01MH90001","R01MH064173"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.pnpbp.2013.05.010","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T22:42:45Z","timestamp":1369780965000},"page":"178-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data"],"prefix":"10.1016","volume":"45","author":[{"given":"Takashi","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Bies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce G.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Graff-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5 Pt 1","key":"10.1016\/j.pnpbp.2013.05.010_bb0005","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1525-1497.2004.30091.x","article-title":"The use of \u201coverall accuracy\u201d to evaluate the validity of screening or diagnostic tests","volume":"19","author":"Alberg","year":"2004","journal-title":"J Gen Intern Med"},{"issue":"9","key":"10.1016\/j.pnpbp.2013.05.010_bb0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4088\/JCP.08m04307yel","article-title":"Positron emission tomography measurement of dopamine D(2) receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia","volume":"71","author":"Arakawa","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2013.05.010_bb0015","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.pnpbp.2010.02.019","article-title":"Hyperprolactinaemia in early psychosis \u2014 not only due to antipsychotics","volume":"34","author":"Aston","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2013.05.010_bb0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF00589893","article-title":"Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels","volume":"99","author":"Baron","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"year":"1992","series-title":"NONMEM user's guide, part I","author":"Beal","key":"10.1016\/j.pnpbp.2013.05.010_bb9005"},{"issue":"12","key":"10.1016\/j.pnpbp.2013.05.010_bb0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.JGP.0000224330.73063.6c","article-title":"Population pharmacokinetics in geriatric psychiatry","volume":"14","author":"Bigos","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2013.05.010_bb0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"Bigos","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.pnpbp.2013.05.010_bb0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.pnpbp.2013.05.010_bb0040","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.pnpbp.2013.05.010_bb0045","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"1 Suppl. 1","key":"10.1016\/j.pnpbp.2013.05.010_bb0050","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1097\/00004714-199502001-00004","article-title":"Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients","volume":"15","author":"Farde","year":"1995","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.pnpbp.2013.05.010_bb0055","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10401230209147453","article-title":"The effects of atypical antipsychotics on serum prolactin levels","volume":"14","author":"Hamner","year":"2002","journal-title":"Ann Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2013.05.010_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1185\/030079903125002865","article-title":"Hyperprolactinaemia and antipsychotic therapy in schizophrenia","volume":"20","author":"Hummer","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"10 Suppl. 17","key":"10.1016\/j.pnpbp.2013.05.010_bb0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900026304","article-title":"Treatment adherence and long-term outcomes","volume":"12","author":"Kane","year":"2007","journal-title":"CNS Spectr"},{"issue":"4","key":"10.1016\/j.pnpbp.2013.05.010_bb0080","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0075","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood\u2013brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4088\/JCP.v69n0307","article-title":"Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo\u2013pituitary\u2013gonadal axis and reduces bone mineral density in male patients with schizophrenia","volume":"69","author":"Kishimoto","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2013.05.010_bb9015","first-page":"CD006627","article-title":"Ziprasidone versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"10.1016\/j.pnpbp.2013.05.010_bb0090","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.pnpbp.2005.11.037","article-title":"The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients","volume":"30","author":"Lee","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.pnpbp.2013.05.010_bb0095","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pnpbp.2013.05.010_bb0100","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"Mamo","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2013.05.010_bb0105","first-page":"851","article-title":"Management of psychotropic-induced hyperprolactinemia","volume":"11","author":"Marken","year":"1992","journal-title":"Clin Pharm"},{"key":"10.1016\/j.pnpbp.2013.05.010_bb0110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","article-title":"Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia","volume":"184","author":"Meaney","year":"2004","journal-title":"Br J Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2013.05.010_bb9000","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","article-title":"Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patient","volume":"66","author":"Melkersson","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2013.05.010_bb0115","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/ajp.2007.164.4.630","article-title":"Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia","volume":"164","author":"Mizrahi","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2013.05.010_bb0120","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0002-9378(87)80159-X","article-title":"Age-related changes in the female hormonal environment during reproductive life","volume":"157","author":"Musey","year":"1987","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/appi.ajp.163.3.396","article-title":"A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone","volume":"163","author":"Remington","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2013.05.010_bb0135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/JCP.0b013e3181faf0e3","article-title":"Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment","volume":"30","author":"Rettenbacher","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0140","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/schbul\/sbr189","article-title":"Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data","volume":"39","author":"Sakurai","year":"2013","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02246671","article-title":"Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT","volume":"124","author":"Schlegel","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.pnpbp.2013.05.010_bb0150","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","article-title":"Estimation of population characteristics of pharmacokinetic parameters from routine clinical data","volume":"5","author":"Sheiner","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"10.1016\/j.pnpbp.2013.05.010_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2013.05.010_bb0160","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-013-3012-1","article-title":"Dopamine D(2\/3) occupancy of ziprasidone across a day: a within-subject PET study","author":"Suzuki","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.pnpbp.2013.05.010_bb0170","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.2009.133","article-title":"Predicting age-specific dosing of antipsychotics","volume":"86","author":"Uchida","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JGP.0b013e318198776d","article-title":"Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms","volume":"17","author":"Uchida","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0180","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4088\/JCP.08r04171","article-title":"Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms","volume":"70","author":"Uchida","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2013.05.010_bb0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.pnpbp.2013.05.010_bb0190","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.pnpbp.2013.05.010_bb0195","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/schbul\/sbp149","article-title":"Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis","volume":"37","author":"Uchida","year":"2011","journal-title":"Schizophr Bull"},{"issue":"2","key":"10.1016\/j.pnpbp.2013.05.010_bb0165","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FTD.0b013e3182489a6f","article-title":"Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study","volume":"34","author":"Uchida","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.pnpbp.2013.05.010_bb0200","first-page":"E355","article-title":"Quantitative analysis of spontaneous variations of plasma prolactin in normal man","volume":"241","author":"Van Cauter","year":"1981","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.pnpbp.2013.05.010_bb9010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2013.05.010_bb0205","first-page":"1577","article-title":"Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey","volume":"82","author":"Wang","year":"2000","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.pnpbp.2013.05.010_bb0210","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/0091270010387604","article-title":"Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study","volume":"51","author":"Wessels","year":"2011","journal-title":"J Clin Pharmacol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461300105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461300105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:42:36Z","timestamp":1759520556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858461300105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":46,"alternative-id":["S027858461300105X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.05.010","relation":{},"ISSN":["0278-5846"],"issn-type":[{"type":"print","value":"0278-5846"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}